参考文献:1. Shives TC, Dahlin DC, Sim FH, Pritchard DJ, Earle JD. Osteosarcoma of the spine. J Bone Joint Surg Am. 1986;68:660鈥?. 2. Ottaviani G. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3鈥?3. CrossRef 3. Mirabello L, Troisi RJ, Savage S. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531鈥?3. This article is one of the few articles surveying a large database about the incidence and survival rates for osteosarcoma. CrossRef 4. Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PC. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet. 2003;11:611鈥?. CrossRef 5. Boriani S, De Iure F, Bandiera S, Campanacci L, Biagini R, Di Fiore M, et al. Chondrosarcoma of the mobile spine: report on 22 cases. Spine. 2000;25:804鈥?2. CrossRef 6. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91:1063鈥?2. CrossRef 7. Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Skelet Radiol. 1997;26:325鈥?3. CrossRef 8. de Andrea CE, Reijnders CM, Kroon HM, de Jong D, Hogendoorn PC, Szuhai K, et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene. 2012;31:1095鈥?04. CrossRef 9. Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, van den Broek LJ, Taminiau AH, Cornelisse CJ, et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Gene Chromosome Cancer. 1999;26:237鈥?6. CrossRef 10. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing鈥檚 sarcoma. Cancer Res. 2009;69:1776鈥?1. CrossRef 11. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11:421鈥?. This article provides vital information regarding the molecular features of Ewing鈥檚 Sarcoma. CrossRef 12. van den Berg H, Dirksen U, Ranft A, Jurgens H. Ewing tumors in infants. Pediatr Blood Cancer. 2008;50:761鈥?. CrossRef 13. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973鈥?005. Cancer. 2009;115:3526鈥?6. CrossRef 14. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing鈥檚 sarcoma. J Clin Oncol. 1998;16:1248鈥?5. 15. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:572鈥?0. CrossRef 16. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973鈥?995. Cancer Causes Control. 2001;12:1鈥?1. CrossRef 17. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol. 2011;223:336鈥?6. CrossRef 18. Phadke DM, Lucas DR, Madan S. Fine-needle aspiration biopsy of vertebral and intervertebral disc lesions: specimen adequacy, diagnostic utility, and pitfalls. Arch Pathol Lab Med. 2001;125:1463鈥?. 19. Mukherjee D, Chaichana KL, Gokaslan ZL, Aaronson O, Cheng JS, McGirt MJ. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J Neurosurg Spine. 2011;14:143鈥?0. This article once again surveys the SEER database for the survival of patients with primary osseous neoplasms. Given the rarity of these lesions, much of what is known regarding the epidemiology and prognosis of these lesions comes from this database. CrossRef 20. Mukherjee D, Chaichana KL, Parker SL, Gokaslan ZL, McGirt MJ. Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the Surveillance, Epidemiology, and End Results (SEER) database. Eur Spine J. 2013;22:1375鈥?2. This article once again surveys the SEER database for the survival of patients with primary osseous neoplasms. Given the rarity of these lesions, much of what is known regarding the epidemiology and prognosis of these lesions comes from this database. CrossRef 21. York JE, Berk RH, Fuller GN, Rao JS, Abi-Said D, Wildrick DM, et al. Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg. 1999;90:73鈥?. These articles provide significant evidence for the en bloc resection of chrodoma and chondrosarcoma. 22. York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74鈥?. discussion 79鈥?0. These articles provide significant evidence for the en bloc resection of chrodoma and chondrosarcoma. 23. Bacci G, Longhi A, Briccoli A, Bertoni F, Versari M, Picci P. The role of surgical margins in treatment of Ewing鈥檚 sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:766鈥?2. CrossRef 24. Bielack S, Carrle D, Casali PG, Group EGW. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137鈥?. 25. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing鈥檚 Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818鈥?9. 26. Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, et al. Prognostic factors in localized Ewing鈥檚 tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646鈥?4. CrossRef 27. Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020鈥?3. CrossRef 28. Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, et al. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer. 2005;41:225鈥?0. CrossRef 29. Stea B, Cavazzana A, Kinsella TJ. Small-cell osteosarcoma: correlation of in vitro and clinical radiation response. Int J Radiat Oncol Biol Phys. 1988;15:1233鈥?. CrossRef
作者单位:Ali K. Ozturk MD (1) Ziya L. Gokaslan MD (1) Jean-Paul Wolinsky MD (1)
1. Department of Neurosurgery, Johns Hopkins University, The Johns Hopkins Hospital, 600 N. Wolfe Street, Meyer Building, 7th floor, Room 109, Baltimore, MD, 21287, USA